- Vitiligo-like depigmentation affected 200 cancer patients receiving immune checkpoint inhibitor therapy.
- Symptoms appeared about 8 months after treatment began, primarily in sun-exposed areas.
- 77.5% of cases occurred in melanoma patients.
- 23% involved patients with other cancers.
- Limitations included the retrospective design and inability to determine the frequency of this side effect across different cancer types or treatment combinations.
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
